Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 27, 2020


(Exact name of registrant as specified in its charter)






(State or other jurisdiction

of incorporation)



File Number)



(IRS Employer

Identification No.)


301 Binney St., Suite 402

Cambridge, MA




(Address of principal executive offices)


(Zip Code)

Registrant’s telephone number, including area code: (617) 401-9975

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


□  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock


The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging Growth Company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Item 7.01. Regulation FD.


On May 27, 2020, Synlogic, Inc. issued a press release providing notice of its Virtual Research & Development Event to be held at 12:30 PM ET on May 27, 2020. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.  


Item 9.01 Financial Statements and Exhibits.


(d)  Exhibits


The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed:


99.1 Press release dated May 27, 2020





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

















Date: May 27, 2020




/s/ Gregg Beloff





Gregg Beloff





Interim Chief Financial Officer








Exhibit 99.1

Synlogic Hosts First Virtual R&D Event

Live Webcast Scheduled to Begin at 12.30 pm ET Today

CAMBRIDGE, Mass., May 27, 2020 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) today will host its first Virtual R&D Event which will include presentations from members of the Synlogic executive team providing an in-depth review of Synlogic's Synthetic Biotic platform and programs for the treatment of metabolic diseases, inflammatory and immune disorders, and cancer. In addition, guest speaker David S. Goldfarb, M.D., Professor of Medicine and Physiology, NYU School of Medicine, Clinical Chief, Nephrology Division, NYU Langone Health, Chief, Nephrology Section, New York VA Medical Center, will present an overview of enteric hyperoxaluria and a patient perspective.

Registration information for the event can be accessed under "Event Calendar" in the Investors & Media section of the Synlogic website. The R&D Event presentations are scheduled to begin at 12:30 pm ET today, May 27, 2020. A live audio webcast of the presentation and a slide deck will be available via the company's Investor Relations website. Following the live webcast, an archived version will be available on the website for 90 days.

About Synlogic

Synlogic is pioneering the development of a novel class of living medicines, Synthetic BioticTM medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease. When delivered orally, Synthetic Biotic medicines are designed to function in the gut to compensate for the dysfunctional metabolic pathway and have a systemic effect, with the potential to significantly improve symptoms of disease for affected patients. The Company's lead program in this area, SYNB1618, targets PKU. In addition, the Company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including inflammatory and immune disorders, and cancer. Synlogic's first immuno-oncology program, SYNB1891, is in clinical development for the treatment of solid tumors and lymphoma. For more information, please visit

CONTACT: Media Contact: Caroline Rufo, Ph.D., MacDougall, Phone: 781-235-3060, Email:, Investor Contact: Elizabeth Wolffe, Ph.D., Synlogic, Inc., Phone: 617-207-5509, Email: